



#4
1645

RECEIVED
JAN 10 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: YongQi Mu
Title: GLYCOPEPTIDE DISULFIDE AND THIOESTER DERIVATIVES
Docket No.: 1343.005US1 Serial No.: 09/847,048
Filed: May 1, 2001 Due Date: N/A
Examiner: Unknown Group Art Unit: 1645


Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

A return postcard.
 An Information Disclosure Statement (1 p.), Form 1449 (2 p.), and copies of 21 cited references.

Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: 
Atty: Robert J. Harris, Ph.D.
Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 8th day of November, 2001.

Name Alesia G. Dunbar

Signature 

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)
(GENERAL)

IDS/44
1/1/02
PATENT

S/N 09/847,048


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: YongQi Mu
Serial No.: 09/847,048
Filed: May 1, 2001
Title: GLYCOPEPTIDE SULFIDE AND THIOESTER DERIVATIVES

Examiner: Unknown

Group Art Unit: 1645

Docket: 1343.005US1



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant further request that a copy of the 1449 form, initialled by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Under 37 C.F.R. § 1.97(b)(3), it is believed that no fee or certificate is required with this Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicant's Representatives at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

YONGQI MU

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 359-3265

Date 11-8-01

By 

Robert J. Harris, Ph.D.
Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 8 day of November, 2001.


Alisia G. Dunbar

Name

Signature



RECEIVED
TECH CENTER 1600/2900
JAN 10 2002



RECEIVED
JAN 10 2002
TECH CENTER 1600
2001

Sheet 1 of 2

Form 1449*

Atty. Docket No.: 1343.005US1

Serial No. 09/847,048

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

Applicant: YongQi Mu

Filing Date: May 1, 2001

Group: 1645

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,643,987	02/17/1987	Nagarajan et al.	514	8	08/14/85
	4,698,327	10/06/1987	Nagarajan et al.	514	8	04/18/86
	4,727,064	02/23/1988	Pitha	514	58	05/29/85
	4,983,586	01/08/1991	Bodor	514	58	03/29/88
	5,591,714	01/07/1997	Nagarajan et al.	514	9	10/13/94
	5,602,112	02/11/1997	Rubinfeld	514	58	08/26/94
	5,750,509	05/12/1998	Malabarba et al.	514	11	04/30/96
	5,840,684	11/24/1998	Cooper et al.	514	11	03/24/95
	5,916,873	06/29/1999	Cooper et al.	514	9	04/01/98

FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	00/39156	07/06/2000	PCT	C07K	9/00		
	00/59528	10/12/2000	PCT	A61K	38/08		
	0667353	08/16/1995	European	C07K	9/00		
	0816378	01/07/1998	European	C07K	9/00		

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

	Allen, N.E., et al., "The Role of Hydrophobic Side Chains as Determinants of Antibacterial Activity of Semisynthetic Glycopeptide Antibiotics", <u>The Journal of Antibiotics</u> , 50 (8), pp. 677-684, (Aug. 1997)
	Ge, M., et al., "Vancomycin Derivatives That Inhibit Peptidoglycan Biosynthesis Without Binding", <u>Science</u> , 284, pp. 507-511, (April 16, 1999)
	Nagarajan, R., et al., "Synthesis and Antibacterial Evaluation of N-Alkyl Vancomycins", <u>The Journal of Antibiotics</u> , XLII (1), pp. 63-72, (Jan. 1989)
	Nicolaou, K.C., et al., "Chemistry, Biology, and Medicine of the Glycopeptide Antibiotics", <u>Angew. Chem. Int. Ed.</u> , 38, pp. 2097-2152, (1999)
	Pavlov, A.Y., et al., "A New Type of Chemical Modification of Glycopeptides Antibiotics: Aminomethylated Derivatives of Eremomycin and Their Antibacterial Activity", <u>The Journal of Antibiotics</u> , 50 (6), pp. 509-513, (June 1997)
	Pavlov, A.Y., et al., "Chemical Modification of Glycopeptide Antibiotics [VC1]", <u>Russian Journal of Bioorganic Chemistry</u> , 24 (9), pp. 570-587, (1998)
	Pavlov, A.Y., et al., "Mono and Double Modified Teicoplanin Aglycon Derivatives on the Amino Acid No. 7; Structure-activity Relationship", <u>The Journal of Antibiotics</u> , 51 (1), pp. 73-78, (Jan. 1998)

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED
JAN 10 2002
TECH CENTER 1600/2900

Sheet 2 of 2

Form 1449*	Atty. Docket No.: 1343.005US1	Serial No. 09/847,048
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: YongQi Mu	
	Filing Date: May 1, 2001	Group: 1645

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

Zang, M., et al., "A review of recent applications of cyclodextrins for drug discovery", Expert Opinion on Therapeutic Patents, 9 (12), 21 p., (1999)

Examiner	Date Considered
----------	-----------------

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.